Study Details

General Information

Compass MDD 006-DOSING ONLY

A Phase III, multicentre, randomised, double-blind, controlled study to investigate the efficacy, safety, and tolerability of two administrations of COMP360 in participants with treatment-resistant depression

ProtocolCOMP 006
Identifier
UID23a39229-bb3d-4a67-9a51-af607db0c7a7
StatusDone - Archived
Phase3
CategoryMajor Depressive Disorder / Adult
Launch Year0
NCT Number-
Created2023-03-15 13:09
Last Updated2025-02-05 15:42

Description

No description provided.

Comment

No comment.

Target Dates

NameDateRequired
Enrollment ClosedNo
Enrollment OpenNo
First Patient First VisitNo
Site Initiation Mtg.2023-06-19No
PI Meeting StartNo
PI Meeting EndNo
PI Meeting ArrivalNo
PI Meeting DepartureNo
Closeout DateNo
Final PatientVisitNo
PreStudy Selection VisitNo
Target Date 12No
Target Date 13No
Target Date 14No

Leadership

RoleStaffLoginRequired
PrincipalVolk, StephenSVolkNo
RecruiterGomez, KathieKGomezNo
CoordinatorSandoval, LarryLSandovalNo
RegulatoryRamirez, ClaudiaCRamirezNo

Custom Fields

No custom fields.

Sponsor & Organization

SponsorCOMPASS Pathfinder Limited
DivisionCOMPASS Pathfinder Limited
TeamCOMPASS Pathfinder Limited
Managing SiteCatalina Research Institute, LLC
Organization

Contacts

IRB Ref
CROICON
CRO Ref
Correspondence0

Opportunity

Probability0
Comment
Status ColorGainsboro
Currency-
Mayra Sibley

2 Hours

Hi there, I'm Jesse and you?
You

3 minutes

My name is Anne Clarc.
Mayra Sibley

40 seconds

Nice to meet you Anne.
How can i help you?